BioNTech, UK to become strategic partner for mRNA cancer therapies
Germany's BioNTech, a company famed for its COVID-19 vaccine, announced Friday that it signed a memorandum to establish a strategic partnership with the UK for mRNA cancer therapies, according to Anadolu Agency.
The partnership aims to provide personalized mRNA cancer therapies for up to 10,000 patients by the end of 2030